Biotech Values

[kris_kade]

I don't think ABT knows either way of DM-1796 getting approved or not. If they knew (somehow) it will not get approved, they would have waited until FDA decision to get out clean.

It's likely that ABT made the decision based on DM-1796's portfolio value. Simple cost of marketing vs ROI. For a big pharma like ABT, while the cost of marketing may not be that high, ROI may not be sufficient enough to warrant continued interest.

Regardless, DEPO would be a winner. ABT will pay their financial obligations per contract and DEPO can still partner with other pharma. I don't think DEPO can force ABT to launch, IMO